Table 2

Univariate analysis of the association of SVR with patients characteristics
SVR No SVR Tot OR 95% CI p
N % N %
Age (years)
40+ 7 33.3 14 66.7 21 1
<40 18 62.1 11 37.9 29 3.27 1.01-10.62 0.048
BMI (kg/m2)
<25 10 41.7 14 58.3 24 1
25+ 15 57.7 11 42.3 26 1.91 0.62-5.88 0.260
IVDUs
Yes 16 47.1 18 52.9 34 1
No 9 56.3 7 43.8 16 1.45 0.44-4.78 0.545
Biopsy staging (Metavir)
F3-F4 2 15.4 11 84.6 13 1
F1-F2 23 62.6 14 37.8 37 9.04 1.74-46.89 0.009
ALT (mU/mL)
60+ 18 45.0 22 55.0 40 1
<60 7 70.0 3 30.0 10 2.85 0.-64-12.64 0.168
HCV genotype
1 8 32.0 17 68.0 25 1
Not 1 17 68.0 8 32.0 25 4.52 1.38-14.82 0.013
aHCV viral load (IU/ml)
High 13 40.6 19 59.4 32 1
Low 12 66.7 6 33.3 18 2.92 0.87-9.78 0.082

acategorized in High (≥6×105 IU/ml) and Low (<6×105 IU/ml).

BMI Body Mass Index, IVDUs Intravenous drug users, SVR Sustained Virologic Response, OR Odds Ratio, CI Confidence Interval.

Iacomi et al.

Iacomi et al. BMC Infectious Diseases 2013 13:374   doi:10.1186/1471-2334-13-374

Open Data